Previous studies have shown expression of the androgen receptor (AR) in premenopausal and postmenopausal endometrium and endometrial cancer tissue, with significantly higher expression in postmenopausal endometrium, endometrial hyperplasia, and low-grade endometrial cancer versus proliferative endometrium. This evidence concerns the gene AR and endometrial cancer.